HKMPY Hikma Pharmaceuticals plc. Forecast, Technical & Fundamental Analysis

HKMPY in upward trend: price rose above 50-day moving average on January 06, 2025

HKMPY moved above its 50-day moving average on January 06, 2025 date and that indicates a change from a downward trend to an upward trend. In of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 06, 2025. You may want to consider a long position or call options on HKMPY as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HKMPY just turned positive on January 06, 2025. Looking at past instances where HKMPY's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for HKMPY crossed bullishly above the 50-day moving average on December 30, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HKMPY advanced for three days, in of 73 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 50-day moving average for HKMPY moved below the 200-day moving average on December 31, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.782) is normal, around the industry mean (58.527). P/E Ratio (32.154) is within average values for comparable stocks, (90.460). HKMPY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.021) settles around the average of (0.122) among similar stocks. P/S Ratio (2.402) is also within normal values, averaging (19.547).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HKMPY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HKMPY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.